Atrasentan Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.75 mg, 1.25 mg, 10 mg
Reference Brands: Xinlay (USA/EU), Vanrafia (USA/LATAM)
Category:
Nephrology
Atrasentan Hydrochloride is available in Tablets
and strengths such as 0.75 mg, 1.25 mg, 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Atrasentan Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Atrasentan Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Atrasentan hydrochloride is an oral medication used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of rapid disease progression. IgA nephropathy is a chronic kidney disorder characterized by the buildup of immunoglobulin A (IgA) in the kidneys, leading to inflammation and gradual damage to kidney tissues. One of the key indicators of disease progression in these patients is elevated protein levels in the urine, commonly measured by the urine protein-to-creatinine ratio.
Atrasentan belongs to a class of medicines known as endothelin receptor antagonists. It works by selectively blocking endothelin-A receptors, which play a significant role in kidney inflammation, fibrosis, and increased protein leakage through the kidneys. By inhibiting this pathway, atrasentan helps reduce proteinuria and may contribute to slowing the progression of kidney damage in patients with IgA nephropathy.
The medicine is taken orally and is generally prescribed as part of a comprehensive treatment plan that may include supportive kidney care and monitoring by healthcare professionals. Atrasentan represents an important targeted therapy option for patients with progressive kidney disease, helping manage proteinuria and supporting long-term kidney health outcomes.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing